Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669896 | 0.92 | CCR2 (0.68) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL3960926 | 0.90 | CCR2 (0.80) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL28109529 | 0.88 | PLA2G10 (0.64) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL13701158 | 0.87 | CCR2 (0.69) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL27640635 | 0.86 | CCR2 (0.65) | CCR2ALDH1A1CYP1A2POLBGPR35 | |
| SCHEMBL5378162 | 0.85 | CCR2 (1.00) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL5254835 | 0.85 | CCR2 (0.67) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL7423428 | 0.85 | CCR2 (0.56) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL3960264 | 0.84 | CCR2 (0.61) | CCR2ALDH1A1CYP1A2POLBMCL1 | |
| SCHEMBL700800 | 0.84 | ALDH1A1 (0.69) | CCR2ALDH1A1CYP1A2POLBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9221836-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-29 | — | — | US | disclosed |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-07-09 | — | — | US | disclosed |
| US-9045436-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-8664380-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-04 | — | — | US | disclosed |
| US-8466282-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| CN-102123990-A | Heterocyclic compounds and their use | TAKEDA PHARMACEUTICAL | 2011-07-13 | — | — | CN | disclosed |
| EP-2297114-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137587-A1 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-06-03 | — | — | US | disclosed |
| WO-2009154300-A2 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-23 | — | — | WO | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264733-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | CCR2 4492/4885ALDH1A1 156/4885CYP1A2 30/4885 |
| US-20110178057-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | CCR2 4470/4885ALDH1A1 286/4885CYP1A2 39/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | CCR2 1386/4885ALDH1A1 2808/4885CYP1A2 461/4885 |
| US-20150191486-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | CCR2 4492/4885ALDH1A1 156/4885CYP1A2 30/4885 |
| US-20160046601-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | REN, AGT, ACE | CCR2 4492/4885ALDH1A1 156/4885CYP1A2 30/4885 |
| US-20100137587-A1 | Heterocyclic compound and use thereof | REN, AGT, ACE | CCR2 4492/4885ALDH1A1 156/4885CYP1A2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.